Medication info

Linaglipton Duo Tablet 2.5/500 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Jinyang Pharmaceutical Co., Ltd.
Appearance
Bright yellow oval film-coated tablet
Packaging
60 tablets/box [(10 tablets/PTPX6)]
Approval status
Expired

MFDS item code 202003653 · Approved 2020.05.19

This product's status changed to Expired on 2025.05.19. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of blood glucose control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Switching from concomitant linagliptin and metformin therapy: Patients switching from concomitant linagliptin and metformin therapy to this medicine should take the same doses of linagliptin and metformin they were previously taking as the initial dose. 3. Patients inadequately controlled with concomitant insulin and metformin therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). No studies have been conducted to assess the safety and efficacy of switching patients from other oral antihyperglycemic agents to this medicine. Any change in type 2 diabetes treatment may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the initial dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Do not administer to the following patients).

Ingredients

Manufacturer
Jinyang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty in controlling blood sugar
View approved original text

This medication is used to help control blood sugar levels in patients with adult type 2 diabetes. It can be administered when controlling blood sugar is difficult despite dietary and exercise therapy. It is effective even when administered alone to patients with no prior experience of diabetes medication therapy. Additionally, this medication can be used in combination with linagliptin and metformin or when insulin and metformin are not adequately controlling blood sugar. When blood sugar control is difficult with combination therapy of metformin and empagliflozin, this medication can be administered alongside empagliflozin to enhance effectiveness. It is used to improve blood sugar control in various treatment situations.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Switching from concomitant linagliptin and metformin therapy: Patients switching from concomitant linagliptin and metformin therapy to this medicine should take the same doses of linagliptin and metformin they were previously taking as the initial dose. 3. Patients inadequately controlled with concomitant insulin and metformin therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). No studies have been conducted to assess the safety and efficacy of switching patients from other oral antihyperglycemic agents to this medicine. Any change in type 2 diabetes treatment may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the initial dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Do not administer to the following patients).

Precautions

This medication may cause a serious side effect called lactic acidosis, so it should not be used in patients with impaired kidney function or liver function issues. It should also be avoided in patients with type 1 diabetes or patients with acute diseases such as acute myocardial infarction and severe infections. It should not be used in individuals allergic to any of the components included in this medication. There is a risk of hypoglycemia; therefore, caution is required when using this medication in conjunction with other blood sugar-lowering agents like insulin or sulfonylureas, and dosage adjustments might be necessary. During treatment, kidney function should be tested regularly, and immediate consultation with a doctor is necessary if kidney function declines. If an iodine contrast agent used in radiological examinations is administered, the use of this medication should be suspended before and after the examination, and kidney function should be verified. Women who are pregnant or breastfeeding are advised not to use this medication, and those planning to become pregnant should consult their doctor. Safety and efficacy have not been established in children and adolescents, so it is not recommended. Elderly patients should have their dosage adjusted and kidney function checked frequently due to the possibility of declining kidney function. If symptoms such as sudden abdominal pain, muscle weakness, or difficulty breathing occur during treatment, patients should immediately report to their doctor and seek treatment. This medication can be taken regardless of meals, but to minimize gastrointestinal discomfort, it may be beneficial to take it during or after meals. Overdosing on this medication increases the risk of lactic acidosis, so the prescribed dosage must be strictly adhered to. Alcohol consumption should be avoided while taking this medication, and any new medications started or stopped before or after this medication should be discussed with a healthcare professional.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficient vitamin B12
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
Show 128 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • stomatitis
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • metastasis to the liver
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage kidney disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • confusional state
  • nocturia
  • pruritus
  • hypertension
  • erectile dysfunction
  • goiter
  • decreased hemoglobin
  • increased blood potassium
  • increased blood creatinine
  • increased blood creatine phosphokinase
  • male-pattern baldness
  • hyperhidrosis
  • hair loss
  • dermatitis
  • anxiety
  • insomnia
  • depression
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • rectal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • stomatitis
  • increased blood sugar
  • facial edema
  • hyperthermia
  • back pain
  • osteoarthritis
  • limb pain
  • rotator cuff syndrome
  • dizziness
  • diabetic neuropathy
  • headache
  • subdural effusion
  • voice disorder
  • epistaxis
  • hearing loss
  • dizziness
  • dyslipidemia
  • hypercholesterolemia
  • thyroid nodule

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly closed container. Additionally, it is important to store it at room temperature between 1 degree and 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Bright yellow oval film-coated tablet

Package unit

60 tablets/box [(10 tablets/PTPX6)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.